HEMOGLOBINOPATHIES MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-193939 | Health Care
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Hemoglobinopathies Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL HEMOGLOBINOPATHIES MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL HEMOGLOBINOPATHIES MARKET
7.1 GLOBAL HEMOGLOBINOPATHIES MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Abbott Laboratories (United States)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Bio-Rad Laboratories, Inc. (United States)
16.3 Danaher Corporation (United States)
16.4 Siemens AG (Germany)
16.5 Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China)
16.6 Nexcelom Bioscience LLC (United States)
16.7 Nihon Kohden Corporation (Japan)
16.8 PerkinElmer Inc. (United States)
16.9 Apotex Inc. (Canada)
16.10 CRISPR Therapeutics (Switzerland)
16.11 Sysmex Corporation (Japan)
16.12 Novartis AG (Switzerland)
16.13 Medunik USA Inc (United States)
16.14 Emmaus Medical, Inc (United States)
16.15 Bristol-Myers Squibb (United States)
16.16 Alnylam Pharmaceuticals, Inc. (United States)
16.17 Gamida Cell (Israel)
16.18 Biogen Inc. (United States)
16.19 Acceleron Pharma, Inc (United States)
16.20 Sangamo Therapeutics (United States)
16.21 CELGENE CORPORATION (United States)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeThalassemia (Alpha Thalassemia Beta Thalassemia)
Sickle Cell Disease
Other Hb Variants Diseases
By Application
Blood Testing
Genetic Testing
Pre-Implantation Genetic Diagnosis (PGD)
Others
By Therapy Type
Blood transfusion
Iron chelation therapy
Bone marrow transplant
Others
By Test Type
Red Blood Cell (RBC) Count Test
Genetic Testing
Liquid Chromatography (HPLC) Test
Hemoglobin Isoelectric (Hb IEF) Focusing
Hemoglobin Electrophoresis (Hb ELP) Test
Hemoglobin Solubility Test
By End User
Diagnostics Laboratories
Hospitals
Clinics
Others
Companies
Abbott Laboratories (United States)
Bio-Rad Laboratories, Inc. (United States)
Danaher Corporation (United States)
Siemens AG (Germany)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China)
Nexcelom Bioscience LLC (United States)
Nihon Kohden Corporation (Japan)
PerkinElmer Inc. (United States)
Apotex Inc. (Canada)
CRISPR Therapeutics (Switzerland)
Sysmex Corporation (Japan)
Novartis AG (Switzerland)
Medunik USA Inc (United States)
Emmaus Medical, Inc (United States)
Bristol-Myers Squibb (United States)
Alnylam Pharmaceuticals, Inc. (United States)
Gamida Cell (Israel)
Biogen Inc. (United States)
Acceleron Pharma, Inc (United States)
Sangamo Therapeutics (United States)
CELGENE CORPORATION (United States)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.